The Relationship Between Triglyceride to High-Density Lipoprotein Cholesterol Ratio and Cardiovascular High-Risk: A Cross-Sectional Investigation

Pengcheng Li,[1,2†] Jirui Cai,[2†] Shuaifang Yuan,[2] Yapeng Li,[1] Huiting Shi,[1] Cui Liang,[1] Bing He,[2] Qiaotao Xie,[2] Baocang Lei,[2] Jing Bai,[2] Nan Wang,[2] Dongliang Liu,[2] Qichao Wang,[2] Jianwei Xiong,[2] Jin Wang,[2] Haoran Wang,[2]

[1]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

[2]Luohe Central Hospital, Luohe Medical College, Luohe, China

Corresponding to: Haoran Wang, Luohe Central Hospital, Luohe Medical College, Luohe, China

Alternate corresponding author: Jin Wang, Luohe Central Hospital, Luohe Medical College, Luohe, China

[†]Pengcheng Li and Jirui Cai contributed equally to this work.

Abstract

Aims

The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio reflects the balance between atherogenic and anti-atherogenic lipid fractions. The study aims to investigate the utility of the TG/HDL-C ratio in identifying high-risk groups for cardiovascular disease (CVD) within the general population.

Methods

The current study was a branch of the ChinaHEART cohort in middle China that involved a total of 6,593 community-dwelling adults. We examine the association between TG/HDL-C and CVD high-risk in a cross-sectional investigation.

Results

Results from restricted cubic spline and ROC analyses revealed a significant relationship between higher TG/HDL-C levels and increased odds of cardiovascular high-risk, with the ratio exhibiting good discriminatory power (AUC=0.819 in the fully adjusted model). Logistic

regression further supported this association, indicating a 1.21-fold rise in the odds of high-risk for each unit increase in TG/HDL-C.

Conclusions

The TG/HDL ratio demonstrates potential as a valuable clinical tool for CVD prevention. By incorporating the TG/HDL ratio into risk assessment models, healthcare professionals can enhance risk stratification and identify high-risk individuals who may benefit from targeted interventions.

Key words:

TG/HDL-C ratio; cardiovascular high-risk; cross-sectional study; public health.

Introduction

Cardiovascular diseases (CVD) continue to be a leading cause of mortality and morbidity worldwide, imposing a significant burden on healthcare systems and society as a whole. Early identification of individuals at high risk of developing CVD is crucial for implementing targeted prevention and management strategies.(2) Traditional risk factors such as hypertension, dyslipidemia, smoking, and diabetes have been

52 widely recognized, but there is a growing interest in exploring novel
53 biomarkers that may enhance risk stratification in the general
54 population.(3)

55 In recent years, the triglyceride to high-density lipoprotein
56 cholesterol (TG/HDL-C) ratio has emerged as a potential marker for
57 cardiovascular risk assessment.(4–8) This ratio reflects the balance
58 between atherogenic and anti-atherogenic lipid fractions. and has been
59 proposed as a simple and cost-effective tool to identify individuals at
60 increased risk of CVD. Some studies have found that this indicator is
61 associated with morbidity and mortality from cardiovascular disease.(4,9)
62 However, there is still a lack of relevant studies on whether this indicator
63 can identify high-risk groups of cardiovascular disease in the general
64 population.

65 Our study aims to address this gap in knowledge by conducting a
66 cross-sectional observational study to evaluate the utility of the
67 TG/HDL-C ratio in identifying high-risk individuals for cardiovascular
68 diseases in the general population. By examining this novel biomarker in
69 a large and diverse sample, we seek to elucidate its potential as a

70 screening tool for early risk stratification and intervention. If we can
71 effectively identify individuals at high risk of cardiovascular disease in
72 the general population using this indicator, we can intervene at earlier
73 stages of cardiovascular disease, thereby maximizing the prevention of
74 major adverse cardiovascular events.

75 ## Methods

76 ### Study population and data collection

77 The current study is a branch of the China Health Evaluation And
78 risk Reduction through nationwide Teamwork (ChinaHEART) in Luohe
79 City, involving 6,859 community-dwelling adults recruited from two
80 township hospitals in Luohe City between November 2, 2021 and
81 February 20, 2022. The ChinaHEART cohort is a population cohort
82 launched by the China National Center for Cardiovascular Diseases
83 (NCCD) initially aiming at cardiovascular disease (CVD) risk screening
84 and management.(10) Study methods has been described previously.(11)
85 The study strictly adhered to ethical guidelines, with approval granted by
86 the Ethics Committee of Fuwai Hospital and the Ethics Committee of
87 Luohe Central Hospital. Participants received detailed information on the

study's purpose, significance, and risks before participant, in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants. The inclusion criteria for this study are as follows: (1) Age: 35-75 years (born between January 1, 1946, and December 31, 1986); (2) Residing near the survey site for at least 6 months in the 12 months prior to screening; (3) Voluntarily participating in this project and signing the informed consent form. The exclusion criteria are as follows: (1) Survey participants with missing data; (2) Survey participants who answered "unclear" to questionnaire items; (3) Survey participants with fasting time less than 8 hours before blood collection.

We utilized standardized questionnaires to collect data on socio-demographic characteristics (e.g., age, gender), lifestyle factors (e.g., smoking, alcohol consumption), medical history (including hypertension, diabetes, dyslipidemia, coronary heart disease, myocardial infarction, stroke), and medication usage (such as antihypertensive, hypoglycemic, and lipid-lowering drugs) of the study participants. Data were collected through an information system provided by the ChinaHEART study and was uploaded directly to the national study

center in the Fuwai Hospital. The anonymous data used in the current study was applied from the national study center in the Fuwai Hospital after they performed data washing. Cardiovascular disease (CVD) was defined as a diagnosis of coronary heart disease, previous myocardial infarction, or stroke. Body mass index (BMI) was calculated as body mass in kilograms divided by the square of height in meters. Waist circumference was measured by placing a measuring tape horizontally around the abdomen at the midpoint between the anterior superior iliac crest and the lower edge of the twelfth rib. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured in a seated resting position at least twice, and the average values were recorded. Lipid profiles were assessed using fingertip blood samples.

According to the risk assessment prediction map in the Guidelines for Cardiovascular Risk Assessment and Management issued by the World Health Organization in 2008, the risk assessment of cardiovascular disease was conducted.(12) If the screening subjects had 10 years of risk of cardiovascular disease 20%, they were judged as high risk.

Statistics

The study population was categorized based on quartiles of the TG/HDL-C ratio for basic characteristic description. Normality of continuous variables was assessed using the Kolmogorov-Smirnov test, with mean ± standard deviation for normally distributed data, and median (25%-75% interval) for non-normally distributed data. Categorical variables were described using percentages. Distribution differences in high cardiovascular risk proportions across TG/HDL-C ratio quartile populations were illustrated with a percentage stacking bar graph. Continuous variable comparisons between groups involved t-tests or analysis of variance for normally distributed data, and rank sum tests for non-normally distributed data. Chi-square tests were conducted for categorical variable comparisons. The association between the TG/HDL-C ratio and cardiovascular high risk was examined using logistic regression analysis, with two models utilized: one without confounder adjustments for univariate analysis, and another adjusting for confounding factors including gender, age, marital status, BMI, waist circumference, fasting blood glucose, smoking history, alcohol

141 consumption history, diabetes, and systolic and diastolic blood pressure.
142 Nonlinear associations between the TG/HDL-C ratio and cardiovascular
143 risk were explored through restricted cubic spline analysis, utilizing key
144 points at the 10th, 25th, 50th, 75th, and 90th percentiles of the
145 TG/HDL-C ratio. The ability of the TG/HDL-C ratio to identify high
146 cardiovascular risk was evaluated using receiver operating characteristic
147 (ROC) curve analysis. While conducting the ROC curve analysis, we
148 calculated the appropriate cutoff value, and this cutoff value was used to
149 divide the participants into the high and low TG/HDL-C groups for
150 further logistic regression analysis. Furthermore, we used net
151 reclassification improvement (NRI) index to quantify the added value of
152 TG/HDL-C for the discriminative performance.

153 **Results**

154 A total of 6,593 participants with sufficient data were included in the
155 study, comprising 1,417 individuals categorized as cardiovascular
156 high-risk and 5,176 individuals in the non-high-risk category. The study
157 cohort was stratified into four segments based on the TG/HDL-C ratio,
158 highlighting notable variations in demographic and clinical characteristics

159 such as age, gender, height, weight, BMI, waist circumference, smoking
160 habits, alcohol consumption, history of hypertension, diabetes, as well as
161 levels of glucose, lipids, and blood pressure (refer to Table 1). The
162 distribution of high-risk individuals across these quartiles was 16%, 15%,
163 18%, and 38% respectively (view Figure 1).

164 To explore the nonlinear relationship between the TG/HDL-C ratio
165 and cardiovascular high-risk, a restricted cubic spline analysis was
166 conducted. The analysis revealed a positive association between elevated
167 TG/HDL-C ratio levels and an increased likelihood of cardiovascular
168 high-risk (see Figure 2).

169 The TG/HDL-C ratio's discriminatory ability in identifying
170 individuals at cardiovascular high-risk was evaluated through ROC
171 analysis (refer to Figure 3). Initially, in model 1, the AUC for the
172 TG/HDL-C ratio alone was 0.562 (95% CI 0.544-0.580) for all
173 participants. However, upon incorporating all covariates into the analysis
174 in model 2, the AUC significantly increased to 0.819 (95% CI
175 0.805-0.834), suggesting the enhanced effectiveness of combining the
176 TG/HDL-C ratio with traditional cardiovascular risk factors for high-risk

identification. Notably, the NRI index showed a significant improvement in discriminative performance, with a value of 0.107 ± 0.030 ($p = 0.016$). Moreover, the ROC analysis identified the optimal cutoff value for the TG/HDL-C ratio as 1.18, enabling the classification of participants into high and low TG/HDL-C ratio groups.

The logistic regression analysis results examining the relationship between the TG/HDL-C ratio and cardiovascular high-risk are detailed in Table 2. In Model 1, a 1 unit increase in the TG/HDL-C ratio was associated with a 1.40-fold increase in the odds of cardiovascular high-risk (95% CI 1.30-1.51, $p < 0.001$). Comparatively, the high TG/HDL-C ratio group exhibited 1.61 times higher odds of high-risk than the low TG/HDL-C ratio group (95% CI 1.43-1.81, $p < 0.001$), while the highest quartile of the TG/HDL-C ratio had 1.79 times higher odds compared to the lowest quartile (95% CI 1.52-2.10, $p < 0.001$). In Model 2, each 1 unit rise in the TG/HDL-C ratio was associated with a 1.21-fold increase in the odds of cardiovascular high-risk (95% CI 1.11-1.32, $p < 0.001$). Additionally, the high TG/HDL-C ratio group demonstrated 1.27 times higher odds of high-risk compared to the low TG/HDL-C ratio

195 group (95% CI 1.10-1.47, p = 0.001), with the highest quartile of the
196 TG/HDL-C ratio displaying 1.49 times higher odds than the lowest
197 quartile (95% CI 1.21-1.83, p < 0.001).

198 ## Discussion

199 Cardiovascular disease (CVD) remains a significant global health
200 burden, necessitating the identification of individuals at high risk for
201 effective prevention and intervention strategies. The TG/HDL-C ratio has
202 emerged as a potential marker for assessing cardiovascular risk in the
203 general population. It has been observed that the ratio of TG/HDL-C ratio
204 not only provides an approximation of insulin resistance but also assists
205 in identifying patients with an atherogenic lipoprotein profile.(13) The
206 typical lipoprotein phenotype in insulin-resistant/hyperinsulinemic
207 patients is typified by high plasma TG and low HDL cholesterol levels,
208 smaller and denser LDL particles, as well as an increased accumulation of
209 remnant lipoproteins after a meal. This lipoprotein phenotype is not only
210 associated with insulin resistance, but it is also linked with an elevated
211 risk of cardiovascular disease.(14) Although plasma TG and HDL
212 cholesterol levels are commonly tested, the same cannot be said for the

213 LDL particle diameter or postprandial remnant concentrations.
214 Nonetheless, a previous study observed a robust correlation between the
215 TG/HDL cholesterol ratio and the LDL peak diameter.(15) Moreover, it is
216 suggested that a TG/HDL cholesterol concentration ratio of 3.5 can
217 accurately predict the presence of the small dense LDL phenotype (LDL
218 phenotype B). Therefore, by assessing plasma TG and HDL cholesterol
219 levels and computing their ratio, it is possible to obtain understanding
220 into three out of the four modifications in lipoprotein metabolism that
221 enhance the risk of cardiovascular disease in insulin-resistant patients.
222 Numerous epidemiological studies have examined the relationship
223 between the TG/HDL ratio and CVD risk. Most of these studies have
224 reported a positive association between a higher TG/HDL ratio and
225 increased CVD risk. For instance, a prospective cohort study by Gaziano
226 et al. found the ratio of triglycerides to HDL was a strong predictor of
227 myocardial infarction;(16) Urbina et al. suggests the TG/HDL ratio may
228 be a useful marker for identifying young individuals at risk for
229 developing arterial stiffness, an early sign of CVD;(17) Li et al. found a
230 positive correlation between the TG/HDL-C ratio and carotid intima

231 thickness, a marker of early atherosclerosis, in adolescents with type 2
232 diabetes;(18) Du et al. found that the TG/HDL ratio is associated with
233 insulin resistance, a major risk factor for CVD, in a Chinese
234 population;(19) Ren et al. found that the TG/HDL ratio is positively
235 associated with insulin resistance in newly diagnosed type 2 diabetes
236 patients, indicating an increased risk of CVD;(20) Squillace et al. found
237 that a higher TG/HDL ratio is predictive of the development of diabetes, a
238 major risk factor for CVD;(21) Hong et al. found that a high TG/HDL
239 ratio is associated with an increased risk of cardiovascular events in
240 patients with diabetes and coronary artery disease.(22)

241 The TG/HDL ratio holds clinical significance as a potential marker
242 for CVD prevention. It provides valuable insights into the balance
243 between TG and HDL levels, representing the interplay between
244 dyslipidemia and atherosclerosis. A higher TG/HDL ratio reflects an
245 increased atherogenic lipid profile and has been associated with arterial
246 stiffness, carotid intima thickness, insulin resistance and diabetes, all of
247 which contribute to CVD development. By incorporating the TG/HDL

248 ratio into risk assessment models, clinicians can more accurately identify
249 individuals at high risk for CVD and implement targeted interventions.
250 Despite the clinical significance of the TG/HDL ratio, several
251 limitations must be acknowledged. First, the cut-off values for defining
252 high TG/HDL ratios vary across studies, leading to heterogeneity in
253 research findings. Standardization of these thresholds is necessary to
254 ensure consistency and comparability between studies. Additionally,
255 confounding factors, including age, sex, lifestyle factors, and
256 comorbidities, may influence the association between the TG/HDL ratio
257 and CVD risk. Although some studies have attempted to account for these
258 factors, further research is needed to elucidate their precise impact.
259 Moreover, variations in laboratory methods for lipid profile assessment
260 may introduce measurement errors and affect the accuracy of TG and
261 HDL cholesterol estimations.
262 In conclusion, the TG/HDL ratio demonstrates potential as a
263 valuable clinical tool for CVD prevention. Its ability to capture the
264 interplay between triglycerides and HDL cholesterol provides a
265 comprehensive assessment of the atherogenic lipid profile. By

incorporating the TG/HDL ratio into risk assessment models, healthcare professionals can enhance risk stratification and identify high-risk individuals who may benefit from targeted interventions. However, standardization of cut-off values, better control of confounding factors, and harmonization of laboratory methods are needed to further validate the clinical significance of the TG/HDL ratio. With these advancements, the TG/HDL ratio could significantly contribute to the prevention and control of cardiovascular disease.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author Haoran Wang, upon reasonable request.

Declaration of Interest statement

The authors declared that there is no conflict of interest.

Author Contributions statement

Conceptualization and Methodology: Haoran Wang, Pengcheng Li; Formal analysis: Pengcheng Li, Jirui Cai, Shuaifang Yuan, Yapeng Li, Huiting Shi, Cui Liang, Bing He; Data Curation: Qiaotao Xie, Baocang Lei,Jing Bai, Nan Wang, Dongliang Liu, Qichao Wang, Jianwei Xiong,

Jin Wang, Haoran Wang; Writing: Pengcheng Li, Jirui Cai, Shuaifang Yuan, Yapeng Li, Huiting Shi, Cui Liang; Funding acquisition: Qiaotao Xie, Haoran Wang, Pengcheng Li.

Fundings

The study is supported by grants from the National Natural Science Foundation of China (81803318, 82304229), Henan Provincial Science and Technology Research Project (232300420069, 232102310231, 232300420289), and the Henan Ministry of Education (22B320003). The funders have no role in the design and implementation of the current study.

Ethical statement

This study was conducted with approval from the Ethics Committee of Fuwai Hospital (2014–574) as the Central Ethic, and was approved by the Ethics Committee of Luohe Central Hospital as the local ethic. This study was conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all participants.

References

1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. *J Am Coll Cardiol* (2020) 76:2982–3021. doi: 10.1016/j.jacc.2020.11.010

2. Zhao D, Liu J, Xie W, Qi Y. Cardiovascular risk assessment: a global perspective. *Nat Rev Cardiol* (2015) 12:301–311. doi: 10.1038/nrcardio.2015.28

3. Thupakula S, Nimmala SSR, Ravula H, Chekuri S, Padiya R. Emerging biomarkers for the detection of cardiovascular diseases. *Egypt Heart J* (2022) 74:77. doi: 10.1186/s43044-022-00317-2

4. Yang M, Rigdon J, Tsai SA. Association of triglyceride to HDL cholesterol ratio with cardiometabolic outcomes. *J Investig Med Off Publ Am Fed Clin Res* (2019) 67:663–668. doi: 10.1136/jim-2018-000869

5. Kosmas CE, Rodriguez Polanco S, Bousvarou MD, Papakonstantinou EJ, Peña Genao E, Guzman E, Kostara CE. The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease. *Diagnostics* (2023) 13:929. doi: 10.3390/diagnostics13050929

6. Che B, Zhong C, Zhang R, Pu L, Zhao T, Zhang Y, Han L. Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors: an analysis of UK biobank data. *Cardiovasc Diabetol* (2023) 22:34. doi: 10.1186/s12933-023-01762-2

7. Chen C, Dai J-L. Triglyceride to high-density lipoprotein cholesterol (HDL-C) ratio and arterial stiffness in Japanese population: a secondary analysis based on a cross-sectional study. *Lipids Health Dis* (2018) 17:130. doi: 10.1186/s12944-018-0776-7

8. Chen Y, Chang Z, Liu Y, Zhao Y, Fu J, Zhang Y, Liu Y, Fan Z. Triglyceride to high-density lipoprotein cholesterol ratio and cardiovascular events in the general population: A systematic review and meta-analysis of cohort studies. *Nutr Metab Cardiovasc Dis NMCD* (2022) 32:318–329. doi: 10.1016/j.numecd.2021.11.005

9. Chen Z, Chen G, Qin H, Cai Z, Huang J, Chen H, Wu W, Chen Z, Wu S, Chen Y. Higher triglyceride to high-density lipoprotein cholesterol ratio increases cardiovascular risk: 10-year prospective study in a cohort of Chinese adults. *J Diabetes Investig* (2020) 11:475–481. doi: 10.1111/jdi.13118

10. Wang R, Yang Y, Lu J, Cui J, Xu W, Song L, Wu C, Zhang X, Dai H, Zhong H, et al. Cohort Profile: ChinaHEART (Health Evaluation And risk Reduction through nationwide Teamwork) Cohort. *Int J Epidemiol* (2023) 52:e273–e282. doi: 10.1093/ije/dyad074

11. Lu J, Xuan S, Downing NS, Wu C, Li L, Krumholz HM, Jiang L. Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project pilot. *BMJ Open* (2016) 6:e010200. doi: 10.1136/bmjopen-2015-010200

12. WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. *Lancet Glob Health* (2019) 7:e1332–e1345. doi: 10.1016/S2214-109X(19)30318-3

13. Reaven GM. The insulin resistance syndrome. *Curr Atheroscler Rep* (2003) 5:364–371. doi: 10.1007/s11883-003-0007-0

14. Lorenzatti AJ, Toth PP. New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. *Eur Cardiol* (2020) 15:1–9. doi: 10.15420/ecr.2019.06

15. Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted

362 plasma (FER(HDL)). *Clin Biochem* (2001) 34:583–588. doi:
363 10.1016/s0009-9120(01)00263-6

364 16. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL,
365 Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of
366 myocardial infarction. *Circulation* (1997) 96:2520–2525. doi:
367 10.1161/01.cir.96.8.2520

368 17. Urbina EM, Khoury PR, McCoy CE, Dolan LM, Daniels
369 SR, Kimball TR. Triglyceride to HDL-C ratio and increased arterial
370 stiffness in children, adolescents, and young adults. *Pediatrics* (2013)
371 131:e1082-1090. doi: 10.1542/peds.2012-1726

372 18. Li X, Deng Y-P, Yang M, Wu Y-W, Sun S-X, Sun J-Z.
373 Triglyceride to high-density lipoprotein cholesterol ratio and carotid
374 intima-medial thickness in Chinese adolescents with newly
375 diagnosed type 2 diabetes mellitus. *Pediatr Diabetes* (2016)
376 17:87–92. doi: 10.1111/pedi.12250

377 19. Du T, Yuan G, Zhang M, Zhou X, Sun X, Yu X. Clinical
378 usefulness of lipid ratios, visceral adiposity indicators, and the
379 triglycerides and glucose index as risk markers of insulin resistance.
380 *Cardiovasc Diabetol* (2014) 13:146. doi:
381 10.1186/s12933-014-0146-3

382 20. Ren X, Chen ZA, Zheng S, Han T, Li Y, Liu W, Hu Y.
383 Association between Triglyceride to HDL-C Ratio (TG/HDL-C) and
384 Insulin Resistance in Chinese Patients with Newly Diagnosed Type 2
385 Diabetes Mellitus. *PloS One* (2016) 11:e0154345. doi:
386 10.1371/journal.pone.0154345

387 21. Squillace N, Lorenzini P, Lapadula G, Bandera A,
388 Cozzi-Lepri A, Rusconi S, Puoti M, Castagna A, Antinori A, Gori A,
389 et al. Triglyceride/HDL ratio and its impact on the risk of diabetes
390 mellitus development during ART. *J Antimicrob Chemother* (2016)
391 71:2663–2669. doi: 10.1093/jac/dkw185

392 22. Yang S-H, Du Y, Li X-L, Zhang Y, Li S, Xu R-X, Zhu
393 C-G, Guo Y-L, Wu N-Q, Qing P, et al. Triglyceride to High-Density

394 Lipoprotein Cholesterol Ratio and Cardiovascular Events in
395 Diabetics With Coronary Artery Disease. *Am J Med Sci* (2017)
396 354:117–124. doi: 10.1016/j.amjms.2017.03.032

397

Tables

Table 1. Clinical characteristics of the study population by quartiles of TG/HDL-C.

	Q1	Q2	Q3	Q4	p-value
Number	N=1,648	N=1,648	N=1,648	N=1,649	
Age (median (IQR))	59.00 (50.00-67.00)	58.00 (50.00-67.00)	58.00 (51.00-66.00)	58.00 (52.00-66.00)	0.78
Male (%)	617 (37%)	613 (37%)	599 (36%)	667 (40%)	0.081
BMI (median (IQR))	24.12 (22.14-26.32)	24.80 (22.70-26.83)	25.15 (23.16-27.44)	26.04 (24.01-28.36)	<0.001
Waist (median (IQR))	83.00 (77.00-89.95)	85.00 (79.00-91.00)	86.00 (80.50-93.00)	89.00 (82.00-95.00)	<0.001
SBP (median (IQR))	135.00 (123.25-148.50)	136.00 (124.50-149.50)	136.00 (125.50-149.50)	141.50 (129.50-152.00)	<0.001
DBP (median (IQR))	82.50 (76.00-89.50)	82.50 (76.00-89.50)	82.50 (76.00-90.00)	85.00 (77.00-92.50)	<0.001
Current smoke (%)	338 (21%)	325 (20%)	300 (18%)	358 (22%)	0.083
Drinking (%)	86(5%)	68(4%)	98(6%)	107(6%)	0.018
HTN (%)	335(20%)	338(21%)	367(22%)	467(28%)	<0.001
DM (%)	72(4%)	96(6%)	91(6%)	147(9%)	<0.001
CHD (%)	36(2%)	25(2%)	19(1%)	13(1%)	0.006
Stroke (%)	63(4%)	37(2%)	41(2%)	40(2%)	0.021
TC (median (IQR))	4.08 (3.47-4.65)	4.53 (4.03-5.11)	4.97 (4.36-5.43)	5.62 (4.98-6.39)	<0.001
HDL (median (IQR))	1.71 (1.49-1.97)	1.50 (1.33-1.69)	1.39 (1.23-1.52)	1.21 (1.09-1.37)	<0.001
TG (median (IQR))	1.21 (0.95-1.62)	1.41 (1.11-1.74)	1.58 (1.25-2.00)	1.94 (1.47-2.69)	<0.001
LDL (median (IQR))	1.96 (1.45-2.44)	2.48 (2.09-2.88)	2.71 (2.32-3.17)	3.35 (2.71-4.03)	<0.001
Glu (median (IQR))	5.40 (5.10-5.80)	5.40 (5.10-5.90)	5.40 (5.11-6.00)	5.70 (5.30-6.40)	<0.001
TG/HDL-C (median (IQR))	2.43 (2.20-2.59)	3.02 (2.88-3.15)	3.55 (3.41-3.72)	4.50 (4.17-4.97)	<0.001
CVD_highrisk (%)	257 (16%)	251 (15%)	290 (18%)	620 (38%)	<0.001

Data are presented as median (IQR) for continuous variables, and number (percentage) for categorical variables. HTN, hypertension; DM, diabetes mellitus; CHD, coronary heart disease; BMI, body mass index; TC, total cholesterol; TG, triglyceride; LDL, low density lipoprotein; HDL, high density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Table 2. Association between TG/HDL-C ratio and cardiovascular high-risk by logistic regression.

	Model 1		Model 2	
	OR (95% CI)	**p**	**OR (95% CI)**	**p**
All participants				
TG/HDL-C (per 1 unit)	1.40 (1.30-1.51)	<0.001	1.21 (1.11-1.32)	<0.001
TG/HDL-C (high vs low)	1.61 (1.43-1.81)	<0.001	1.27 (1.10-1.47)	0.001
TG/HDL-C (quartile)				
Q1	Ref		Ref	
Q2	0.90 (0.75-1.07)	0.214	1.04 (0.85-1.29)	0.68
Q3	0.84 (0.71-1.01)	0.06	0.95 (0.77-1.18)	0.634
Q4	1.79 (1.52-2.10)	<0.001	1.49 (1.21-1.83)	<0.001
Female				
TG/HDL-C (per 1 unit)	1.36 (1.24-1.50)	<0.001	1.14 (1.01-1.28)	0.028
TG/HDL-C (high vs low)	1.52 (1.30-1.77)	<0.001	1.16 (0.96-1.40)	0.114
TG/HDL-C (quartile)				
Q1	Ref		Ref	
Q2	0.94 (0.74-1.19)	0.6	0.97 (0.74-1.28)	0.838
Q3	0.91 (0.72-1.15)	0.447	1.00 (0.76-1.32)	0.998
Q4	1.78 (1.44--2.20)	<0.001	1.33 (1.02-1.74)	0.034
Male				
TG/HDL-C (per 1 unit)	1.50 (1.33-1.69)	<0.001	1.31 (1.14-1.52)	<0.001
TG/HDL-C (high vs low)	1.82 (1.51-2.19)	<0.001	1.45 (1.15-1.84)	<0.001
TG/HDL-C (quartile)				
Q1	Ref		Ref	
Q2	0.85 (0.66-1.11)	0.238	1.14 (0.84-1.57)	0.432
Q3	0.78 (0.59-1.03)	0.076	0.90 (0.64-1.27)	0.557
Q4	1.94 (1.51-2.49)	<0.001	1.67 (1.20-2.32)	0.002

Figure legends

Figure 1. Percentage stacked histogram to visually represent the distribution of cardiovascular high-risk individuals across quartiles of the TG/HDL-C ratio.

Figure 2. Distribution histogram of the TG/HDL-C ratio in the study population and restricted cubic spline to assess the relationship between TG/HDL-C ratio and cardiovascular high-risk.

Figure 3. ROC curve to illustrate the discriminatory power of TG/HDL-C ratio for cardiovascular high-risk.



Figure 1. Percentage stacked histogram to illustrate the distribution of cardiovascular high-risk according to quartiles of TG/HDL-C ratio.



Figure 2. Distribution histogram of the TG/HDL-C ratio in the study population and restricted cubic spline to assess the relationship between TG/HDL-C ratio and cardiovascular high-risk.



Figure 3. ROC curve to illustrate the discriminatory power of TG/HDL-C for cardiovascular high-risk.